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Female, pecliatric, and older donors have bee~D~ 
elated with iDfer10r paft IlU'Vivai after reDaI. traD8-
plantation. We anaIyzecl these three sublP'Oups°in 88'7 
patients receivina tacrolhnua-bued. immunosuppres-
sion. There were no cWrerences in recipient age, inci-
dence of retransplantation, or percentage of 8eD8l-
tized patients. Female donors, compared with male 
donors, were 8880Clated with comparable 1- and a-year 
patient 81U"Vlval rates (98% and 93% VB. 95% and 91%, 
respectively) and comparable 1- and a-year graft sur-
vival rates (90% and 80% va. 88% and 81 %, respective-
ly). Renal function was also slmilar. Recipients of 
pediatric en bloc kidneys, when compared with recip-
ients of other cadaveric kidneys, also had comparable 
1- and a-year patient survival rates (94% and 94% VB. 
95% and 91%, respectively) and comparable 1- and 
a-year graft survival rates (84% and 84% VB. 89% and 
79%, respectively). Renal function was better in recip-
ients of en bloc kidneys, with a mean serum creatinine 
level of 1.4%1.8 mgldl vs. 2.0%1.5 mg/dl (P=O.OI). In 
contrast to the first two subgroups, donors over 80 
yean of age, when compared with donors under 80 
yean of age, were associated with worse 1- and a-year 
patient survival rates (88% and 80% vs. 98% and 94%, 
respectively; P<O.03) and worse 1- and a-year graft 
survival rates (74% and 62% vs. 91% and 83%, respec-
tively; P<O.OOOl). Renal function was worse in the 
older donor group, with a serum creatinine level of 
2.7:U.2 mglml vs. 1.9%1.5 mgldl (P=O.Ol). 
We conclude that, under tacrolimus-based immuno-
suppression, kidneys from female or very young pedi-
atric donors are not associated with adverse out-
comes, whereas kidneys from donors over 80 yean of 
age are 8880Ciated with inferior outcomes. 
A potential conflict in renal transplantation relates to the 
interest in using "expanded criteria" donors to increase the 
stagnant organ supply, and the importance of the "quality" of 
a given kidney and its impact on long-term outcome. There 
have been many reports of inferior outcomes with kidneys 
1 Thomas E. Starzl Transplantation Institute, University of Pitts-
burgh. 
2 Address correspondence to: Ron Shapiro, MD. 4th Floor Falk, 
3601 Fifth Avenue. Pittsburgh, PA 15213. 
3 Division of Urologic Surgery, University of Pittsburgh. 
4 Montefiore Medical Center and the Albert Einstein College of 
Medicine. 
S Division of Transplant Pathology, University of Pittsburgh. 
6 Division of General and Vascular Surgery, University of Pitts-
burgh. 
from female donors, pediatric donors, aDa" older donors 
(1;;'16), and many theories advanced to a:pliiDtheae findings 
(16,11). In view of the improving results ~ported With ta-
crolimus-based immunosuppression in reD8I\ranaplantation 
(18-23), we thought it would be useful to lCiOkat these three 
different subgroups in some detail, with a view toward per-
haps modifying our notions of what constitutes a truly "sub-
optimal" donor. This analysis was performed on a well-stud-
ied group of patients who entered a prospective, randomized, 
open-label trial of tacrolimus/prednisone versus tacrolimusl 
azathioprine/prednisone, between August 1, 1991, and De-
cember 9, 1993 (20). 
MATERIALS AND METHODS 
A total of 397 kidney transplantations were perf'orm.ed during the 
course of the above-mentioned trial. The details of the donor and 
recipient population, immunosuppressive protoc:ola, and overall out-
comes have been reported previously (18-20). In this analysis, we 
compared outcomes with kidneys from female (n-l66) versus male 
(n=231) donors, en bloc kidneys from pediatric donors 3 years of age 
or younger (n=50) versus kidneys from other, i.e., mostly adult 
cadaveric donors (n=308), and kidneys from donors over (n=43) 
versus donors under (n=354) the age of 60 yean (Table 1). None of 
the subgroups differed significantly in terms of recipient age or 
percentage of recipients over 60, nor did they dift'er in tenns of the 
percentage of recipients undergoing retransplantation or having a 
panel reactive antibody (PRA·) level over 40%. Parameters studied 
were I-year actual and 3-year actuarial patient and graft survival 
rates, measures of renal function, and the incidence of delayed graft. 
function and rejection. The two immunosuppressive groups were 
pooled for the purposes of the subgroup analyses, to allow for ade-
quate sample size. ° 
Statistical analysis. Continuous variables were described as the 
mean :t SD, and categorical variables were described as proportions. 
The standard two-sample t test was used to teat dift'erences be-
tween means, and differences in proportions were tested using Pear-
son's chi-square test or Fisher's exact test if expected frequencies 
were less than 5. The Wilcoxon rank sum test, a nonparametric 
equivalent to the standard two-sample t test, was used for highly 
skewed data. 
Patient survival rates were calculated from the date of kidney 
transplantation until death. and graft survival rates from the date of 
kidney transplantation until graft failure, retransplantation, or pa· 
tient death. Survival curves were generated using the Kaplan-Meier 
(product-limit) method and compared using the log-rank (Mantel-
Cox) test. Cox's proportional hazards model was used to compute the 
relative risk of graft failure and 95% confidence intervals. All tests 
• Abbreviations: BUN. blood urea nitrogen; PRA, panel reactive 
antibody. 
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TABLE 1. Donor and recipient characteristics" 
Donor Donor age Recipient age 
subgroup (yr) (yr) 
Female (n=166) 35.9:!::21.9 44.3±14.2 
Male (n=231) 32.7:!::19.4 44.9±14.0 
En bloc (n=50) 1.4±1.l 43.4±15.0 
Other cadaver (n=30S) 3S.3±lS.1 45.6±14.0 
>60 yr (n=43) 65.4:!::3.3 45.3±13.3 
s60 yr (n=354) 30.2:!::lS.4 44.6+14.2 
Retransplant 
n(%) 
34 (21) 
66 (29) 
8(16) 
88 (29) 
6 (14) 
94 (27) 
moA~4M% 
n (%) 
19 (11) 
34 (15) 
5 (10) 
47 (15) 
2 (5) 
51 (14) 
Recipient >60 yr 
n(%) 
28 (17) 
44 (19) 
12 (24) 
59(19) 
7 (16) 
65 (18) 
"P-NS for recipient age, retransplants, PRA ~4M%I and recipients >60 years old. 
were two-tailed. A P-value of less than 0.05 was considered statisti-
"" c:ally significant. 
'
" ::, . This study was performed before tacrolimus received approval 
'from the U.S. Food and Drug Administration. In view of the study's 
·prospecti~eI randomized design, local institutional review board ap-
,,' proval, WIth yearly renewal, was routinely sought and granted. 
~IKI .-...... .. ". 
d RESULTS 
The mean follow-up period was 33::!:10 months for all sub-
group analyses. 
Female donors versus male darwrs. There were no differ-
ences in outcomes between recipients of female or male kid-
neys (Fig. 1). One-year actual and 3-year actuarial patient 
survival rates were 96% and 93% with female donors and 
95% and 92% with male donors, respectively. The corre-
sponding graft survival rates were 90% and 80% for female 
donors and 88% and 81% for male donors, respectively. The 
mean serum creatinine level, blood urea nitrogen (BUN) 
level, and calculated creatinine clearance were 1.9±1.7 mgt 
dl, 29±15 mg/dl, and 58:!:27 mlImin, for female donors, and 
1:9::!:1.2 mg/dl, 31±15 mg/dl, and 54:!:23 mlImin, respec-
tively, for male donors (Table 2). The incidences of delayed 
graft function and rejection were also not different. 
Pediatric en bloc donors versus other cadaveric donors. In 
this subgroup analysis, I-year actual and 3-year actuarial 
patient survival rates were similar and were 94% and 94% 
for en bloc recipients, and 95% and 91% for recipients of all 
other cadaveric kidneys (Fig. 2). Graft survival rates were 
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FIGURE L Patient and graft survival rates in recipients of kidneys 
from female versus male donors. For patient survival: -- = male 
donors (n=230). - - - - - = female donors (n= 165). P=0.516 (Jog rank). 
For graft survival: 0-0 = male donors (n=231), 0- - -0 = female 
donors In= 166). P=O.559 (Jog rank). 
also similar overall, and were 84% at 1 year and 3 years for 
en bloc recipients, and 89% and 79% for other cadaveric 
recipients. The measures of renal function were significantly 
better in the en bloc recipients (Table 2), with a lower mean 
serum creatinine level and BUN level and higher calculated 
creatinine clearance (1.4:!:1.8 mg/dl, 23:!:9 mg/dl, and 69:!:24 
mlImin, vs. 2.0::!:1.5 mg/dl, 32:!:16 mg/dl, and 52:!:23 mlImin, 
respectively), than in the other cadaveric recipients (P=O.Ol 
for serum creatinine, P<O.OOOl for BUN, and P<0.0001 for 
calculated creatinine clearance). In addition, while the inci-
dence of delayed graft function was not different (30% vs. 
39%), the incidence of rejection was significantly lower in the 
en bloc recipients (30% vs. 55%; P<O.OOl). 
Donors over versus dorwrs under 60 years of age. There 
were marked differences in outcomes between recipients of 
kidneys from donors over and donors under 60 years of age 
(Fig. 3). Patient survival rates at 1 year and 3 years in the 
over-60 group were significantly worse ( 88% and 80%) than 
in the under-60 group ( 96% and 94%; P<0.03). There was no 
discernible pattern regarding the causes of death: cardiac 
disease, infectious problems, intracranial hemorrhage, and 
malignancy were all observed. Graft survival was also worse 
with 74% and 62%, versus 91% and 83%, 1- and 3-yea; 
outcomes (P=0.001), in the over-60 and under-60 groups, 
respectively. While donor disease was noted in several pa-
tients losing their allografts, chronic allograft nephropathy 
was the most common cause of graft failure. Renal function 
was worse (Table 2), with a higher mean serum creatinine 
level and BUN level and lower calculated creatinine clear-
ance in the over-60 group. Delayed graft function was seen in 
54% of the over-60 group, significantly more than in the 
under-60 group (33%; P=0.006). In addition, the incidence of 
rejection was significantly higher in the over-60 group (67%) 
than in the under-60 group (48%; P<0.02) . 
DISCUSSION 
In the United States, over 30,000 individuals are on the 
waiting list for renal transplantation, and this number in-
creases at a rate at over 2000 patients/year (24, 25). Thus, 
there is an active interest in expanding the donor pool. How-
ever, an important question with these expanded-criteria 
donor organs is whether they are of sufficient quality to 
justify their use. Our data with three different groups of 
"suboptimal" donors in patients treated with tacrolimus are 
reassuring for two of these categories and are troubling for 
the third. 
The lack of effect of donor sex on any parameter of outcome 
or function is at variance with many published reports in the 
transplant literature U-9, 26). Explanations for worse out-
comes have included factors such as the nephrotoxicity of 
• 
i, ! : 
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TABLE 2. Outcomes 
Serum creatinine 
(mgldl) 
BUN Creatinine clearance Delayed graft 
function (%) 
Rejection 
(%) (mgldl) (mJImin) 
Female 
Male 
En bloc 
Other cadaver 
>60 years 
s60 years 
II P=O.Ol. 
b P=O.OOOI. 
• P=O.OOI. 
dp<0.03. 
- P"O.OO6. 
fp<0.02. 
10 
~ 60 
--] 
t 40 
til 
20 
.' 
1.9±1.7 
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FIGURE 2. Patient and graft survival rates in recipients of en bloc 
kidneys from pediatric donors versus other cadaveric donors. For 
patient survival: -- = en bloc (n=50), - - - - - = other cadaveric 
(n=306), P=0.596 (log rank). For graft survival: 0-0 = en bloc 
(n=50), D· - -0 = other cadaveric (n=308), P=0.440 (log rank). 
cyclosporine, and decreased renal mass, or "nephron dose," of 
female donors (16,17). We have seen no evidence of any such 
effect under tacrolimus, an agent that is generally thought to 
exhibit nephrotoxicity comparable to that seen with cyclospo-
rine (27-31). The lack of donor sex effect may well be simply 
a function of the superiority of tacrolimus as an immunosup-
pressive agent, evidence for which is becoming increasingly 
apparent (20, 21, 23). Since the donor sex effect has largely 
been confined to the first 3 months after transplantation, 
perhaps the more efficacious immunosuppression offered by 
tacrolimus has been associated with less early graft loss to 
rejection. 
This greater protection against rejection of an organ with 
less renal mass could also explain the excellent outcomes 
obtained with en bloc kidneys. It is worth noting that there 
was a slight decrement at 1 year in the en bloc cases, possibly 
related to an increased number of technical losses or cases of 
primary nonfunction; these were, however, not sufficient to 
degrade the overall outcome with these kidneys. The fact 
that the renal function is actually better with en bloc kidneys 
is probably a function of the fact that two kidneys are being 
transplanted. In the absence of overwhelming rejection and 
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FIGURE 3. Patient and graft survival rates in recipients of kidneys 
from donors over or under the age of 60. For patient survival: --
= donor age s60 (n=352), - - - - - = donor age >60 (n=43), P=0.OO3 
(log rank). For graft survival: 0-0 = donor age :s60 (n=354), 
0- - -D = donor age >60 (n=43), P=O.OOOI (log rank). 
excessive toxicity, these kidneys can grow and provide excel-
lent renal function over time (32, 33). An argument could be 
made that these small kidneys could be separated and used 
singly (34), and these results are sufficiently encouraging 
that this idea could perhaps be considered for donors over the 
age of 1112 or 2 years. At present, we have little data of our 
own on this issue and have been reluctant to separate kid-
neys from donors less than 3 or 4 years of age. 
The lower rate of rejection observed with en bloc kidneys is 
harder to understand. Although there is a tendency to trans-
plant these kidneys into low PRA recipients undergoing their 
first transplant, the en bloc group did not have significantly 
fewer retransplant or high PRA patients. It is hard to imag-
ine these kidneys being less immunogenic than other cadav-
eric organs. Certainly, in the cyclosporine era, we have had 
anecdotal experience with early overwhelming rejection oc-
casionally destroying these organs. Thus, this observation is 
a bit mysterious. 
Finally, the worse outcomes with older donors are of sig-
nificant concern. Both patient and graft survival were infe-
rior, as was the quality of renal function. Delayed graft 
function and rejection were also seen more frequently than in 
-
9 
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, ~ under-60 group. These poor results could argue against 
"the use of donors over 60 years of age under any circum-
'stances. Parenthetically, these results under tacrolimus are 
substantially better than our experience with these donors 
under cyclosporine-based therapy (35, 36). At present, our 
routine with older donors is to biopsy the kidneys and get an 
immediate frozen section reading, looking specifically at the 
percentage of glomerulosclerosis, as well as a qualitative 
, assessment of arterionephrosclerosis and interstitial fibrosis. 
In addition, the urine output of the donor and the serum 
creatinine over time are also assessed. Anything over 20% 
glomerulosclerosis or more than mild arterionephrosclerosis 
or interstitial fibrosis, or evidence of a falling urine output, or 
~a rising serum creatinine, will lead to rejection of the donor 
; , for transplantation. We are hopeful that these well-
.'GIIlUD1ed, somewhat more selective criteria will allow us to use 
.' from older donors more successfully, but clearly these 
~ults are grounds for increasing conservatism. ' 
" ;,In summary, under tacrolimus-based immunosuppression, 
,;there was no penalty in using female or pediatric en bloc 
~IkidneysI and these two groups of donors should not be con-
siderable suboptimal. Older donors, on the other hand, were 
associated with significantly inferior results. Ifkidneys from 
older donors are to be transplanted, they should be used with 
extreme caution and after careful screening. 
Acknowledgments. We thank Regina Fenton, RN, BSN, Loraine 
Kaminski, RN, BSN, Deborah Good, RN, BSN, Holly Woods, RN, 
Jareen Flohr, RN, BSN, Sue Bauder, RN, Jennifer Ovesney, RN, 
Sharon Orlofske, RN, Mark Paynter, RN, BSN, and Bridget Delaney, 
PAC, for their help with patient care; Janet Schmelzer for her help 
with data entry and organization; Kate Carr for her help with slide 
preparation: and Susan Shandor for her help with typing the manu-
script and preparing the tables and slides. 
REFERENCES 
1. Cecka JM, Terasaki PI. The UNOS Scientific Renal Transplant 
Registry. In: Terasaki PI, Cecka JM, eds. Clinical transplants 
1993. Los Angeles: UCLA Tissue Typing Laboratory, 1994: 1. 
2. Takiff H. Donor factors. In: Terasaki PI, ed. Clinical transplants 
1989. Los Angeles: UCLA Tissue Typing Laboratory, 1990: 
417. 
3. Shibue T, Kondo K, Iwaki Y, Terasaki PI. Effect of sex on kidney 
transplants. In: Terasaki PI, ed. Clinical transplants 1987. Los 
Angeles: UCLA Tissue Typing Laboratory, 1987: 351. 
4. Kenneally P. The impact of sex on kidney transplantation. In: 
Terasaki PI, ed. Clinical kidney transplant 1985. Los Angeles: 
UCLA Tissue Typing Laboratory, 1985: 147. 
5. Zhou YC, Cecka JM. Effect of sex on kidney transplants. In: 
Terasaki PI, ed. Clinical transplant 1989. Los Angeles: UCLA 
Tissue Typing Laboratory 1989: 361. 
6. Koka P, Cecka JM. Sex and age effects in renal transplantation. 
In: Terasaki PI, ed. Clinical transplants 1990. Los Angeles: 
UCLA Tissue Tying Laboratory, 1990: 437. 
7. Cecka JM. Donor factors. In: Terasaki PI, ed. Clinical trans-
plants 1987. los Angeles: UCLA Tissue Typing Laboratory, 
1987: 423. 
8. Yuge J, Cecka JM. Sex and age effects in renal transplantation. 
In: Terasaki PI, ed. Clinical transplants 1991. Los Angeles: 
UCLA Tissue Typing Laboratory, 1991: 257. 
9. Thorogood J. van Houwelingen JC. van Rood JJ, Zantvoom FA. 
Schreuder GMT. Persign GG. Factors contributing to long-
term kidney graft survival in Eurotransplantation. Transplan-
tation 1992: 54: 152. 
10. Hong JH, Shirani K. Arshad A, et al. Influence of cadaver donor 
age on the success of kidney transplants. Transplantation 
1981; 32: 532. 
11. Ploeg RJ, Visser MJT, Stijnen T, Persijn GG, van Schilfgaarde R. 
Impact of donor age and quality of donor kidneys on graft 
survival. Transplant Proc 1987; 19: 1532. 
12. Opelz G. Influence of recipient and donor age in pediatric renal 
transplantation. Transpl Int 1988; 1: 95. 
13. Yuge J, Cecka JM. Pediatric recipients and donors. In: Terasaki 
PI, ed. Clinical transplants 1990. Los Angeles: UCLA Tissue 
Typing Laboratory, 1990: 425. 
14. Alexander JW, Vaughn WK, Carey MA. The use of marginal 
donors for organ transplantation: the older and younger do-
nors. Transplant Proc 1991; 23: 905. 
15. Smith AY, van Buren CT, Lewis RM, Kerman RH, Kahan BD. 
Short-term and long-term function of cadaveric lddDeys from 
pediatric donors in recipients treated with cycloaporine. Trans-
plantation 1988; 45: 360. " -:;gi~Dd~y!;:;;: , 
16. Brenner BM, Milford EL. Nephron underdosing: a programmed 
" cause of chronic renal allograft failure. Am J Kidney Dis 1993; 
21 (suppl 2):66. '" ..-
17. Brenner BM, Cohen RA, Milford EL. In renal transplantation, 
one size may not fit all. J Am Soc Nephro11992; 3: 162. 
18. Shapiro R, Jordan M, Scantlebury V, et al. A prospective, ran-
domized trial of FK506 in renal transplantation: a comparison 
between double and triple drug therapy. Clin Transplant 1994; 
8: 509. 
19. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, 
randomized trial of FK506-based immunosuppression after 
renal transplantation. Transplantation 1995; 59: 485. 
20. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, 
randomized trial of FK506lprednisone vs FK506lazathioprinei 
prednisone in renal transplant patients. Transplant Proc 1995; 
27(1): 814. 
21. Shapiro R, Scantlebury VP, Jordan ML, et a1. FK506 in pediatric 
kidney transplantation-primary and rescue experience. Pedi-
atr Nephrol 1995; 9 (suppl): S43. 
22. Laskow DA, Vincenti F, Neylan J, Mendez R, Matas A. Phase II 
FK506 Multicenter Concentration Control Study: one-year fol-
low-up. Transplant Proc 1995; 22(1): 809. 
23. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of 
FK506 and cyclosporine on short- and long-term kidney graft 
survival. Transplantation 1995; 60(2): 1384. 
24. UNOS Update. 1995; 11(12): 26. 
25. UNOS Update. 1994; 10(12): 27. 
26. Neugarten J, Silbiger SR. The impact of gender on renal trans-
plantation. Transplantation 1994; 58(11): 1145. 
27. McCauley J, Takaya S, Fung J, et a1. The question of FK506 
nephrotoxicity after liver transplantation. Transplant Proc 
1991; 23(1): 1444. 
28. Starzl TE, Abu-Elmagd K, Tzakis A, et a1. Selected topics on 
FK506, with special references to rescue of extrahepatic whole 
organ grafts, transplantation of "forbidden organs,· side ef-
fects, mechanisms, and practical pharmacokinetics. Trans-
plant Proc 1991; 23(1): 914. 
29. Starzl TE. FK506 versus cyclosporine. Transplant Proc 1993; 
25(1): 511. 
30. Demetris AJ, Banner B. Fung JJ. et al. Histopathology of human 
renal allograft function under FK506: a comparison with cy-
closporine. Transplant Proc 1991; 23: 944. 
31. Randhawa PS, Shapiro R. Jordan ML. Starzl TE, Demetris A.1. 
The histopathological changes associated with allograft rejec-
tion and drug toxicity in renal transplant recipients main-
tained on FK506: clinical significance and comparison with 
cyciosporine. Am J Surg Pathol 1993; 17(1): 60. 
32. Nghiem DD, Hsia S. Schlosser JO. Growth and function of en 
bloc infant kidney transplant: a preliminary study. J Urol 
1995; 153(2): 326. 
1246 TRANSPLANTATION Vol. 62, No.9 
33. Darras F, Jordan ML, Shapiro R, et al. Transplantation of pedi-
atric en bloc kidneys under FK 506 immunosuppression. 
Transplant Proc 1991; 23: 3089. 
34. Gruessner RWG, Matas AJ, Lloveras G. A comparison of single 
and double pediatric cadaver donor kidneys for transplanta-
tion. Clin Transplant 1989; 3: 209. 
35. Vivas CA, O'Donovan RM, Jordan ML, et al. Cadaveric renal 
transplantation using kidneys from donors greater than 60 
years old. Clin Transplant 1992; 6: 77. 
36. Vivas CA, Gritsch A, Shapiro R, et al. Cadaveric renal trans-
plantation using donors over 60 years old: 5 year followup. 
Transplant Proc (in press). 
Received 20 March 1996. 
Accepted 13 June 1996. 
T~q·~ 
.;... ,,-.c.. 
-
